...
首页> 外文期刊>Transplantation: Official Journal of the Transplantation Society >Liver transplantation versus liver resection in the treatment of hepatocellular carcinoma: A meta-analysis of observational studies
【24h】

Liver transplantation versus liver resection in the treatment of hepatocellular carcinoma: A meta-analysis of observational studies

机译:肝移植与肝切除术治疗肝细胞癌:观察性研究的荟萃分析

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: A number of cohort studies have compared the outcomes of liver transplantation (LT) and liver resection (LR) in hepatocellular carcinoma (HCC) patients. However, the effects of LT versus LR remain unclear. We searched electronic databases and reference lists for relevant articles published before February 2013. METHODS: The primary endpoints were pooled using random-effects models to model potential heterogeneity, including overall survival (OS), disease-free survival, and recurrence rate. RESULTS: We found similar 1-year OS (odds ratio [OR], 1.08; 95% confidence interval [CI], 0.81-1.43; P=0.61) yet significantly better 3-year OS (OR, 1.47; 95% CI, 1.18-1.84; P<0.001) and 5-year OS (OR, 1.77; 95% CI, 1.45-2.16; P<0.001) after LT compared with LR with relative risk differences of 9% (P<0.001) and 14% (P<0.001), respectively. The 1-, 3-, and 5-year difference-free survival were 13%, 29%, and 39% higher (P<0.001 in all) in LT recipients than LR patients. Additionally, recurrence rate was 30% less (P<0.001) in LT than LR. Furthermore, better 5-year difference-free survival (P<0.001) and recurrence rates (P<0.05) were yielded after LT when patients from the entire HCC population were included. CONCLUSIONS: When including all the 62 previous studies comparing LT and resection, LT provides increased survival and lower recurrence rates than LR for HCC patients. These results of disease-free survival and recurrence rate are similar among early HCC patients with Child-Turcotte-Pugh class A cirrhosis. However, summary ORs and risk differences cannot be interpreted as causal effects of LT versus LR.
机译:背景:许多队列研究比较了肝细胞癌(HCC)患者的肝移植(LT)和肝切除(LR)的结果。但是,LT与LR的影响仍不清楚。我们在电子数据库和参考列表中搜索了2013年2月之前发表的相关文章。方法:使用随机效应模型汇总主要终点,以建模潜在的异质性,包括总体生存期(OS),无病生存期和复发率。结果:我们发现相似的1年OS(赔率[OR]为1.08; 95%置信区间[CI]为0.81-1.43; P = 0.61),但3年OS明显更好(OR为1.47; CI为95%,与LR相比,LT后的1.18-1.84; P <0.001)和5年OS(OR,1.77; 95%CI,1.45-2.16; P <0.001),相对危险度分别为9%(P <0.001)和14% (P <0.001)。与LR患者相比,LT接受者的1年,3年和5年无差异生存率分别高13%,29%和39%(所有P均<0.001)。此外,LT的复发率比LR低30%(P <0.001)。此外,包括整个HCC人群的患者后,LT后的5年无差异生存率(P <0.001)和复发率(P <0.05)更高。结论:当包括所有先前比较LT和切除术的62​​项研究时,与LR相比,LT对HCC患者的生存率更高,复发率更低。无病生存率和复发率的这些结果在早期患有Child-Turcotte-Pugh A级肝硬化的HCC患者中相似。但是,总结性OR和风险差异不能解释为LT与LR的因果关系。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号